Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2017-03-24 Major Shareholding Noti…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2017
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'HealthInvest Partners AB' concerning shares in 'Medivir Aktiebolag'. It explicitly shows the 'Before the transaction' and 'After the transaction' holdings, including the number of shares and voting rights percentages. The section 'Reason for major shareholding notification' confirms the nature of the filing. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2017-03-24 English
Medivir completes transition of commercial products to fully focus on research and development
M&A Activity Classification · 95% confidence The document announces a strategic shift where Medivir outlicenses commercial rights for simeprevir and returns rights for Adasuve, resulting in the company focusing entirely on R&D. This involves changes to its business structure and asset portfolio, which directly impacts its financing and operational structure. While it mentions past revenues, the core event is a significant corporate transaction related to asset management and future revenue streams (royalties/milestones). This aligns best with the Capital/Financing Update (CAP) category, as it fundamentally alters the company's revenue-generating assets and structure, or potentially M&A Activity (TAR) if viewed as an asset divestiture. Given the focus on restructuring revenue streams via out-licensing and milestones, CAP is the most appropriate fit over TAR (which usually implies a merger or takeover bid). It is not an ER, IR, or 10-K as it is not a standard financial results report.
2017-03-16 English
Medivir slutför avyttringen av bolagets kommersiella produkter och renodlar inriktningen på forskning och utveckling
Regulatory Filings Classification · 99% confidence The document text is a press release from Medivir AB announcing the completion of the divestment (avyttringen) of its commercial products and a shift in focus to R&D. It details transactions involving licensing rights (simeprevir) and the return of rights (Adasuve), including financial details (royalties, milestone payments, historical revenue) and strategic implications. This type of announcement, detailing significant corporate transactions, financing changes, or strategic shifts, best fits the 'Capital/Financing Update' category, as it involves restructuring the company's assets and revenue streams, even though it's not a traditional capital raise. It is a specific corporate action announcement. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for a major asset divestment leading to a change in business model, although 'RNS' (Regulatory Filings) could also apply if this were a generic regulatory disclosure. However, the content is highly specific to a transaction, making CAP more precise than the general RNS fallback.
2017-03-16 Swedish
Major Shareholding Notification 2017
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding for a specific instrument (Class B shares and redemption shares) held by 'Paradigm Capital Value Fund SICAV' in 'Medivir Aktiebolag'. It provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, and states the 'Reason for major shareholding notification' as 'Sell'. This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a direct report of the change, not an announcement of a report.
2017-03-14 English
Redovisning av utfallet i Medivirs frivilliga inlösenprogram
AGM Information Classification · 99% confidence The document is titled "Redovisning av utfallet i Medivirs frivilliga inlösenprogram" (Reporting of the outcome of Medivir's voluntary redemption program). It details the results of a share redemption program, including the number of shares tendered, the cash consideration to be paid (approx. 857.5 million SEK), and the resulting post-redemption share count. This clearly relates to a change in the company's capital structure or a specific financing/share transaction. Reviewing the definitions, 'Capital/Financing Update' (CAP) covers fundraising, financing activities, or capital structure changes. 'Transaction in Own Shares' (POS) covers share repurchase/issuance. Since this is a redemption program resulting in a reduction of shares and cash payout, it fits best under Capital/Financing Update (CAP) as it is a major capital structure event, although POS is also relevant. Given the focus on the outcome of a structured program affecting the total number of shares and capital distribution, CAP is the most appropriate high-level classification for a significant capital structure event. It is not an earnings release, an annual report, or a simple dividend notice.
2017-03-03 Swedish
Presentation of the result of Medivir’s voluntary redemption programme
Share Issue/Capital Change Classification · 95% confidence The document announces the final results of a 'voluntary redemption programme' involving the repurchase and distribution of cash proceeds related to company shares. This action directly relates to changes in the company's capital structure, specifically the number of outstanding shares and the distribution of funds to shareholders in exchange for those shares. This aligns best with the definition of 'Capital/Financing Update' (CAP), as it details a significant capital structure change (share redemption and cash distribution). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), but a specific corporate action related to capital.
2017-03-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.